256 related articles for article (PubMed ID: 33064914)
1. Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
Ishiyama KI; Kitawaki T; Otsuka Y; Takaori-Kondo A; Kadowaki N
Cancer Sci; 2021 Feb; 112(2):523-536. PubMed ID: 33064914
[TBL] [Abstract][Full Text] [Related]
2. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph
Ishiyama K; Kitawaki T; Sugimoto N; Sozu T; Anzai N; Okada M; Nohgawa M; Hatanaka K; Arima N; Ishikawa T; Tabata S; Onaka T; Oka S; Nakabo Y; Amakawa R; Matsui M; Moriguchi T; Takaori-Kondo A; Kadowaki N
Leukemia; 2017 Jan; 31(1):203-212. PubMed ID: 27349810
[TBL] [Abstract][Full Text] [Related]
3. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
4. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
5. CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age.
Müller-Durovic B; Grählert J; Devine OP; Akbar AN; Hess C
Aging (Albany NY); 2019 Jan; 11(2):724-740. PubMed ID: 30686790
[TBL] [Abstract][Full Text] [Related]
6. Early Cytomegalovirus Reactivation and Expansion of CD56
Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
Front Immunol; 2018; 9():2433. PubMed ID: 30405627
[TBL] [Abstract][Full Text] [Related]
8. Human peripheral blood DNAM-1
Stannard KA; Lemoine S; Waterhouse NJ; Vari F; Chatenoud L; Gandhi MK; Martinet L; Smyth MJ; Guillerey C
Blood Adv; 2019 Jun; 3(11):1681-1694. PubMed ID: 31167820
[TBL] [Abstract][Full Text] [Related]
9. Proteome analysis of human CD56
Voigt J; Malone DFG; Dias J; Leeansyah E; Björkström NK; Ljunggren HG; Gröbe L; Klawonn F; Heyner M; Sandberg JK; Jänsch L
Eur J Immunol; 2018 Sep; 48(9):1456-1469. PubMed ID: 29999523
[TBL] [Abstract][Full Text] [Related]
10. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
11. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Leukemia; 2011 Oct; 25(10):1587-97. PubMed ID: 21647156
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2018 Jan; 109(1):182-192. PubMed ID: 29058817
[TBL] [Abstract][Full Text] [Related]
13. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection.
Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913
[TBL] [Abstract][Full Text] [Related]
14. A New Hope for CD56
Forconi CS; Oduor CI; Oluoch PO; Ong'echa JM; Münz C; Bailey JA; Moormann AM
Front Cell Infect Microbiol; 2020; 10():162. PubMed ID: 32373555
[TBL] [Abstract][Full Text] [Related]
15. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
16. Immune Dysfunctions of CD56
Cao WJ; Zhang XC; Wan LY; Li QY; Mu XY; Guo AL; Zhou MJ; Shen LL; Zhang C; Fan X; Jiao YM; Xu RN; Zhou CB; Yuan JH; Wang SQ; Wang FS; Song JW
Front Immunol; 2021; 12():811091. PubMed ID: 35069597
[TBL] [Abstract][Full Text] [Related]
17. Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells.
Hamann I; Unterwalder N; Cardona AE; Meisel C; Zipp F; Ransohoff RM; Infante-Duarte C
Immunology; 2011 May; 133(1):62-73. PubMed ID: 21320123
[TBL] [Abstract][Full Text] [Related]
18. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
20. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]